PPBT Purple Biotech Ltd.

NASDAQ
$1.51

Purple Biotech Ltd. (PPBT) is expected to report earnings on November 9, 2026, before the market open. The consensus earnings estimate is a loss of $2.88 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +11.9% since its last earnings release on August 7, 2026.

Purple Biotech Beat Consensus Estimates
Friday, August 7, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 7:00 AM ET
Earnings Whisper
-
vs ($2.88)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.97

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Purple Biotech Ltd.

Purple Biotech Ltd. is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.